Result of General Meeting and Total Voting Rights

RNS Number : 6293G

Destiny Pharma PLC

26 November 2020

 

THIS ANNOUNCEMENT (INCLUDING THE APPENDIX) AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM THE UNITED STATES, AUSTRALIA, CANADA, THE REPUBLIC OF SOUTH AFRICA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. PLEASE SEE THE IMPORTANT NOTICES AT THE END OF THIS ANNOUNCEMENT.

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION

Destiny Pharma plc

("Destiny" or the "Company")

Result of General Meeting

and

Total Voting Rights

Brighton, United Kingdom - 26 November 2020: Destiny Pharma plc (AIM:DEST) a clinical stage biotechnology company focused on the development of novel products to prevent life threatening infections, announces that, at the General Meeting held earlier today, all resolutions proposed were duly passed by shareholders on a poll.

Accordingly, the Company has raised total gross proceeds of approximately 10.4 million from the Fundraising and has allotted a total of 15,951,726 New Ordinary Shares. Admission of the 7,783,288 EIS/VCT Placing Shares is expected to occur on 27 November 2020 and the remaining 8,168,438 New Ordinary Shares, comprised of the General Placing Shares, Subscription Shares and Open Offer Shares, are expected to be admitted on 30 November 2020.

Following General Admission on 30 November 2020, the Company's issued ordinary share capital will comprise 59,816,921 Ordinary Shares, none of which are held in treasury. The above figure of 59,816,921 may be used by Shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the voting rights of the Company under the FCA's Disclosure Guidance and Transparency Rules.

A summary of the votes received for the General Meeting will be made available on the Company's website at www.destinypharma.com.

Unless otherwise defined herein, capitalised terms used in this announcement shall have the same meanings as defined in the announcement of the Fundraising made by the Company on 9 November 2020.

Enquiries:

Destiny Pharma plc	[phone]
Neil Clark (Chief Executive Officer) Shaun Claydon (Chief Financial Officer and Company Secretary)
finnCap Limited - Nominated Adviser and Joint Broker	[phone]
Geoff Nash / Kate Bannatyne / Charlie Beeson (Corporate Finance) Alice Lane (ECM)
WG Partners LLP - Joint Broker	[phone]
Nigel Barnes / Claes Spång / Nigel Birks / Andrew Craig
Optimum Strategic Communications	[phone]
Mary Clark / Shabnam Bashir / Manel Mateus

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

1.	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Neil Clark
2.	Reason for the Notification
a)	Position/status	Chief Executive Officer
b)	Initial notification/Amendment	Initial notification
3.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Destiny Pharma plc
b)	LEI	213800O9WH9Z38EHAC95
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the Financial instrument, type of instrument	Ordinary shares of 1 pence each ("Ordinary Shares")
	Identification code	DEST    GB00BDHSP575
b)	Nature of the transaction	Purchase of Ordinary Shares
c)	Price(s) and volume(s)	Price(s) Volume(s) 65 pence 38,462
d)	Aggregated information: Aggregated volume Price	See 4c) above
e)	Date of the transaction	26 November 2020
f)	Place of the transaction	London Stock Exchange, AIM Market

1.	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Nick Rodgers
2.	Reason for the Notification
a)	Position/status	Chairman
b)	Initial notification/Amendment	Initial notification
3.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Destiny Pharma plc
b)	LEI	213800O9WH9Z38EHAC95
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the Financial instrument, type of instrument	Ordinary shares of 1 pence each ("Ordinary Shares")
	Identification code	DEST    GB00BDHSP575
b)	Nature of the transaction	Purchase of Ordinary Shares
c)	Price(s) and volume(s)	Price(s) Volume(s) 65 pence 38,462
d)	Aggregated information: Aggregated volume Price	See 4c) above
e)	Date of the transaction	26 November 2020
f)	Place of the transaction	London Stock Exchange, AIM Market

1.	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Debra Barker
2.	Reason for the Notification
a)	Position/status	Non-Executive Director
b)	Initial notification/Amendment	Initial notification
3.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Destiny Pharma plc
b)	LEI	213800O9WH9Z38EHAC95
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the Financial instrument, type of instrument	Ordinary shares of 1 pence each ("Ordinary Shares")
	Identification code	DEST    GB00BDHSP575
b)	Nature of the transaction	Purchase of Ordinary Shares
c)	Price(s) and volume(s)	Price(s) Volume(s) 65 pence 38,461
d)	Aggregated information: Aggregated volume Price	See 4c) above
e)	Date of the transaction	26 November 2020
f)	Place of the transaction	London Stock Exchange, AIM Market

 

END

 

 

TVRPPGQCGUPUGUQ